Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications

Current Neuropharmacology, 2016 · DOI: 10.2174/1570159X13666160502153022 · Published: May 2, 2016

Simple Explanation

The brain-gut axis involves peptidergic growth factors native to the GI tract that possess antiulcer potency, potentially benefiting CNS disorders from the periphery. The focus is on BPC 157, a stable gastric pentadecapeptide, known for its antiulcer properties and safety in trials for inflammatory bowel disease and multiple sclerosis. BPC 157 may serve as a mediator of Robert’s cytoprotection, maintaining GI mucosa integrity without toxicity. It has shown success in treating GI tract issues, periodontitis, liver and pancreas lesions, and in healing various tissues and wounds. BPC 157 modulates serotonergic and dopaminergic systems, which beneficially affects behavioral disturbances caused by (over)stimulated/damaged neurotransmitter systems. It also offers neuroprotective effects, aiding in nerve regeneration, counteracting traumatic brain injury, and attenuating encephalopathies.

Study Duration

Not specified

Participants

Rats and Mice

Evidence Level

Review Article

Key Findings

1
BPC 157 exhibits neuroprotective effects, improving nerve regeneration after peripheral nerve transection and counteracting autotomy.
2
BPC 157 attenuates traumatic brain injury, postponing deleterious outcomes and counteracting the primary injury with respect to the secondary injury process.
3
BPC 157 recovers rat tail function after spinal cord injury probably through the abolishment of secondary injury of the spinal cord, and consequently, improved neurological function recovery.

Research Summary

This review explores the theoretical and practical implications of the brain-gut axis, focusing on the stable gastric pentadecapeptide BPC 157 and its potential as a remedy in various CNS disorders. BPC 157 demonstrates a strong beneficial background in the periphery, implying a corresponding beneficial central influence that could be effectively used in further therapy. BPC 157 avoids practical pitfalls for healing using peptidergic growth factors, acting directly and using the same dosage range, offering a suitable therapy and physiology link between the periphery and the central nervous system.

Practical Implications

Novel Therapeutic Agent

BPC 157 may serve as a remedy in various CNS-disorders, offering a new approach to treating conditions like traumatic brain injury, spinal cord injury, and neurodegenerative diseases.

Drug Interaction Mitigation

BPC 157 may counteract side effects of different groups of neuroleptics, typical and atypical, indicating a potential use in reducing adverse effects of psychiatric medications.

Substance Abuse Treatment

BPC 157 could be used in both acute and chronic amphetamine disturbances, as well as alcohol intoxication and withdrawal, suggesting a role in addiction treatment.

Study Limitations

1
Limited clinical application despite promising preclinical results.
2
Mechanism of action not fully elucidated, requiring further investigation of specific molecular pathways.
3
Studies primarily conducted in animal models, necessitating human clinical trials to confirm efficacy and safety.

Your Feedback

Was this summary helpful?

Back to Pharmacology